Intranasal Market
Mystic Value Proposition For Intranasal Drug Delivery
Intranasal drug delivery is expanding as a preferred route of administration because it avoids the issue of drug degradation in the gastrointestinal tract, provides a faster onset of action and is a painless alternative to injections. For many patients, nasal delivery is preferred because it avoids problems associated with swallowing, minimizes gastric distress, improves compliance and potentially reduces the cost of repeated physician visits.
As new drugs and biologics are developed or reformulated for intranasal administration the market need for drug delivery systems that are safe, effective, easy and convenient to use and cost effective to manufacture will grow. Currently, pharmaceutical and biotech manufacturers must either develop their own intranasal drug delivery systems (an expensive and time consuming process) or license such devices from a very limited number of device manufacturers offering limited functionality or complex systems which are costly to manufacture and fill.
Mystic Pharmaceuticals combines the principles of advanced engineering, simple device operation and cost effective “design for manufacturability” to provide drug delivery devices that establish a new industry benchmark.
Value Proposition For Consumers, Caregivers, Physicans and Manufacturers
• Preservative Free Drug Packaging In Unit Dose Form
• Non-invasive delivery
• No “sharps” disposable issues
• Intranasal delivery provides faster onset of action over oral delivery
normally found with injectables
• Self Administered delivery reduces dependency on trained healthcare professionals
for administration of drug
• Mystic VelocityJet™ micropump can be adapted to a wide range of drugs or
biologics, for differing viscosity, delivered dose and spray plume geometry
• Ruggedized device design and “Transport Lock” reduces risk of damage or
inadvertant discharge during transport, storage and handling.
• Security “Lock Up” feature reduces risk of mis-use or abuse after use
• Design For Manufacturability provides cost advantages over competing intranasal
delivery systems and can be scaled to meet global market production volume
requirements
Intranasal drug delivery is expanding as a preferred route of administration because it avoids the issue of drug degradation in the gastrointestinal tract, provides a faster onset of action and is a painless alternative to injections. For many patients, nasal delivery is preferred because it avoids problems associated with swallowing, minimizes gastric distress, improves compliance and potentially reduces the cost of repeated physician visits.
As new drugs and biologics are developed or reformulated for intranasal administration the market need for drug delivery systems that are safe, effective, easy and convenient to use and cost effective to manufacture will grow. Currently, pharmaceutical and biotech manufacturers must either develop their own intranasal drug delivery systems (an expensive and time consuming process) or license such devices from a very limited number of device manufacturers offering limited functionality or complex systems which are costly to manufacture and fill.
Mystic Pharmaceuticals combines the principles of advanced engineering, simple device operation and cost effective “design for manufacturability” to provide drug delivery devices that establish a new industry benchmark.
Value Proposition For Consumers, Caregivers, Physicans and Manufacturers
• Preservative Free Drug Packaging In Unit Dose Form
• Non-invasive delivery
• No “sharps” disposable issues
• Intranasal delivery provides faster onset of action over oral delivery
normally found with injectables
• Self Administered delivery reduces dependency on trained healthcare professionals
for administration of drug
• Mystic VelocityJet™ micropump can be adapted to a wide range of drugs or
biologics, for differing viscosity, delivered dose and spray plume geometry
• Ruggedized device design and “Transport Lock” reduces risk of damage or
inadvertant discharge during transport, storage and handling.
• Security “Lock Up” feature reduces risk of mis-use or abuse after use
• Design For Manufacturability provides cost advantages over competing intranasal
delivery systems and can be scaled to meet global market production volume
requirements